Paper24253594
Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
Dávila-Fajardo CL and 10 others. Pharmacogenet Genomics, 2014. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome. Papers, record 24253594. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24253594
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
- PubMed
Topics25
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antirheumatic Agents | Major topic |
| Arthritis, Rheumatoid | Major topic |
| Immunoglobulin G | Major topic |
| Interleukin-6 | Major topic |
| Promoter Regions, Genetic | Major topic |
| Receptors, Tumor Necrosis Factor | Major topic |
| Tumor Necrosis Factor-alpha | Major topic |
| Adalimumab | |
| Adult | |
| Aged | |
| Antibodies, Monoclonal | |
| Antibodies, Monoclonal, Humanized | |
| Cytosine | |
| Etanercept | |
| Female | |
| Genetic Markers | |
| Genotype | |
| Guanine | |
| Humans | |
| Infliximab | |
| Male | |
| Middle Aged | |
| Polymorphism, Single Nucleotide | |
| Reproducibility of Results | |
| Treatment Outcome |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT02878161 | Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From "Real World" | Background |
Source ClinicalTrials.gov
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41892810 | Genomic Impacts of Biological Exposures. | J Dev Biol | 2026 | https://conductscience.org/library/papers/41892810 | PubMed |
| 37509625 | DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis. | Biomedicines | 2023 | https://conductscience.org/library/papers/37509625 | PubMed |
| 36013214 | Pharmacogenomics of Monoclonal Antibodies for the Treatment of Rheumatoid Arthritis. | J Pers Med | 2022 | https://conductscience.org/library/papers/36013214 | PubMed |
| 36009355 | Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis. | Biomedicines | 2022 | https://conductscience.org/library/papers/36009355 | PubMed |
| 35238332 | Mechanisms underlying DMARD inefficacy in difficult-to-treat rheumatoid arthritis: a narrative review with systematic literature search. | Rheumatology (Oxford) | 2022 | https://conductscience.org/library/papers/35238332 | PubMed |
| 35003068 | Toward Overcoming Treatment Failure in Rheumatoid Arthritis. | Front Immunol | 2021 | https://conductscience.org/library/papers/35003068 | PubMed |
| 33557301 | Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment. | Cells | 2021 | https://conductscience.org/library/papers/33557301 | PubMed |
| 33536774 | Relationship Between Interleukin-6 -174G/C Genetic Variant and Efficacy of Methotrexate Treatment in Psoriatic Arthritis Patients. | Pharmgenomics Pers Med | 2021 | https://conductscience.org/library/papers/33536774 | PubMed |
| 33047210 | IL6 genetic variants haplotype is associated with susceptibility and disease activity but not with therapy response in patients with inflammatory bowel disease. | Int J Colorectal Dis | 2021 | https://conductscience.org/library/papers/33047210 | PubMed |
| 32825059 | Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis. | Biomolecules | 2020 | https://conductscience.org/library/papers/32825059 | PubMed |
| 30283335 | Development of an AmpliSeqTM Panel for Next-Generation Sequencing of a Set of Genetic Predictors of Persisting Pain. | Front Pharmacol | 2018 | https://conductscience.org/library/papers/30283335 | PubMed |
| 30232372 | Genetic variant in IL-32 is associated with the ex vivo cytokine production of anti-TNF treated PBMCs from rheumatoid arthritis patients. | Sci Rep | 2018 | https://conductscience.org/library/papers/30232372 | PubMed |
| 28607508 | Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. | Pharmacogenomics J | 2017 | https://conductscience.org/library/papers/28607508 | PubMed |
| 28600618 | Application of omics in predicting anti-TNF efficacy in rheumatoid arthritis. | Clin Rheumatol | 2018 | https://conductscience.org/library/papers/28600618 | PubMed |
| 28356850 | Influence of Promoter Polymorphisms of the TNF-α (-308G/A) and IL-6 (-174G/C) Genes on Therapeutic Response to Etanercept in Rheumatoid Arthritis. | J Med Biochem | 2015 | https://conductscience.org/library/papers/28356850 | PubMed |
| 27738630 | The -174G/C Interleukin-6 Gene Promoter Polymorphism as a Genetic Marker of Differences in Therapeutic Response to Methotrexate and Leflunomide in Rheumatoid Arthritis. | Biomed Res Int | 2016 | https://conductscience.org/library/papers/27738630 | PubMed |
| 26578807 | Genetic polymorphism directs IL-6 expression in fibroblasts but not selected other cell types. | Proc Natl Acad Sci U S A | 2015 | https://conductscience.org/library/papers/26578807 | PubMed |
| 26526676 | Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis. | Clin Rheumatol | 2015 | https://conductscience.org/library/papers/26526676 | PubMed |
| 26149736 | The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis. | Pharmacogenomics J | 2016 | https://conductscience.org/library/papers/26149736 | PubMed |
| 25990005 | Predictors of response to TNF-α antagonist therapy in Chinese rheumatoid arthritis. | Clin Rheumatol | 2015 | https://conductscience.org/library/papers/25990005 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| TNF | 7124 | PubTator's text mining | https://conductscience.org/library/genes/7124 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24253594
GET https://conductscience.org/api/papers/v1/24253594/cited_by?page=2